Mayowa Soyombo

Mayowa Soyombo

Auto-generated profile, based on publicly available information

Mayowa Soyombo

Oxford Biomedica (UK) Limited, Oxford, United Kingdom

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
RHRichard Harrop
Richard Harrop
DBDaniel G. Blount
Daniel G. Blount
NKNaeem Khan
Naeem Khan
MSMayowa Soyombo
Mayowa Soyombo
LMLaura Moyce
Laura Moyce
AEAnna Ettorre
Anna Ettorre
Chimeric antigen receptor (CAR) T cells represent a novel targeted approach to overcome deficits in the ability of the host immune system to detect and subsequently eradicate tumors. The identification of antigens expressed specifically on the surface of tumor cells is a critical first step for a targeted therapy that selectively targets cancer cells without affecting normal tissues. 5T4 is a tumor-associated antigen expressed on the cell surface of most solid tumors. However, very little is known about its expression in hematologic malignancies. In this study, we assess the expression of 5T4 in different types of leukemias, specifically acute myeloid leukemia (AML), and normal hematopoietic stem cells (HSC). We also provide an in vitro assessment of safety and efficacy of 5T4-targeting CAR T cells against HSCs and AML tumor cell lines. 5T4 expression was seen in about 50% of AML cases; AML with mutated nucleophosmin 1, AML–myelodysplasia-related, and AML not otherwise specified showed the highest percentage of 5T4+ cases. 5T4 CAR T cells efficiently and specifically killed AML tumor cell lines, including leukemic stem cells. Coculture of 5T4 CAR T cells with HSCs from healthy donors showed no impact on subsequent colony formation, thus confirming the safety profile of 5T4. A proof-of-concept study using a murine model for AML demonstrated that CAR T cells recognize 5T4 expressed on cells and can kill tumor cells both in vitro and in vivo. These results highlight 5T4 as a promising target for immune intervention in AML and that CAR T cells can be considered a powerful personalized therapeutic approach to treat AML.

2 January 2025
Verified
Other
Open access
PDF file
RHRichard Harrop
Richard Harrop
DBDaniel G. Blount
Daniel G. Blount
NKNaeem Khan
Naeem Khan
MSMayowa Soyombo
Mayowa Soyombo
LMLaura Moyce
Laura Moyce
AEAnna Ettorre
Anna Ettorre
Supplementary Table 2: 5T4 Expression in AML Cell Lines

17 June 2026
Verified
Other
Open access
PDF file
RHRichard Harrop
Richard Harrop
DBDaniel G. Blount
Daniel G. Blount
NKNaeem Khan
Naeem Khan
MSMayowa Soyombo
Mayowa Soyombo
LMLaura Moyce
Laura Moyce
AEAnna Ettorre
Anna Ettorre
Supplementary Table 1A. Disease information on 5T4+ AML samples ranked by rMFI (all >1.5). Supplementary Table 1B. 5T4+ AML samples ranked by MFC % (all >20%).

17 June 2026
Verified
Other
Open access
RHRichard Harrop
Richard Harrop
DBDaniel G. Blount
Daniel G. Blount
NKNaeem Khan
Naeem Khan
MSMayowa Soyombo
Mayowa Soyombo
LMLaura Moyce
Laura Moyce
AEAnna Ettorre
Anna Ettorre
Supplementary Figure 2. Schematic representation and sequence of 5T4 construct

17 June 2026
Verified
Other
Open access
PDF file
RHRichard Harrop
Richard Harrop
DBDaniel G. Blount
Daniel G. Blount
NKNaeem Khan
Naeem Khan
MSMayowa Soyombo
Mayowa Soyombo
LMLaura Moyce
Laura Moyce
AEAnna Ettorre
Anna Ettorre
Supplementary Table 2: 5T4 Expression in AML Cell Lines

17 June 2026
Verified
Other
Open access
RHRichard Harrop
Richard Harrop
DBDaniel G. Blount
Daniel G. Blount
NKNaeem Khan
Naeem Khan
MSMayowa Soyombo
Mayowa Soyombo
LMLaura Moyce
Laura Moyce
AEAnna Ettorre
Anna Ettorre
Chimeric antigen receptor (CAR) T cells represent a novel targeted approach to overcome deficits in the ability of the host immune system to detect and subsequently eradicate tumors. The identification of antigens expressed specifically on the surface of tumor cells is a critical first step for a targeted therapy that selectively targets cancer cells without affecting normal tissues. 5T4 is a tumor-associated antigen expressed on the cell surface of most solid tumors. However, very little is known about its expression in hematologic malignancies. In this study, we assess the expression of 5T4 in different types of leukemias, specifically acute myeloid leukemia (AML), and normal hematopoietic stem cells (HSC). We also provide an in vitro assessment of safety and efficacy of 5T4-targeting CAR T cells against HSCs and AML tumor cell lines. 5T4 expression was seen in about 50% of AML cases; AML with mutated nucleophosmin 1, AML–myelodysplasia-related, and AML not otherwise specified showed the highest percentage of 5T4+ cases. 5T4 CAR T cells efficiently and specifically killed AML tumor cell lines, including leukemic stem cells. Coculture of 5T4 CAR T cells with HSCs from healthy donors showed no impact on subsequent colony formation, thus confirming the safety profile of 5T4. A proof-of-concept study using a murine model for AML demonstrated that CAR T cells recognize 5T4 expressed on cells and can kill tumor cells both in vitro and in vivo. These results highlight 5T4 as a promising target for immune intervention in AML and that CAR T cells can be considered a powerful personalized therapeutic approach to treat AML.